NewsAstal Laboratories Completes ₹17.50 Crore Preferential Share Allotment to Non-Promoter InvestorsAstal Laboratories Completes ₹17.50 Crore Preferential Share Allotment to Non-Promoter Investors
Astal Laboratories Limited completed a preferential allotment of 17.50 lakh equity shares to non-promoter investors Vupparapalli Chandra Sekhar Reddy and Vupparapalli Pavani on January 14, 2026. The transaction involved warrant conversions and share swap arrangements, increasing the combined shareholding of both investors to 4.86% of total share capital. The company's equity capital expanded from ₹10.77 crores to ₹42.22 crores, with proper regulatory disclosures filed under SEBI regulations.
*this image is generated using AI for illustrative purposes only.
Astal Laboratories Limited has completed a significant preferential share allotment to non-promoter investors, strengthening its equity base through strategic allocation of 17.50 lakh shares on January 14, 2026.
Share Allotment Details
The company allotted shares to two non-promoter investors through different mechanisms:
| Allottee | Shares Allotted | Category | Allotment Basis |
|---|---|---|---|
| Vupparapalli Chandra Sekhar Reddy | 2.50 lakh | Non-Promoter | Conversion of Warrants into equity |
| Vupparapalli Pavani | 12.50 lakh | Non-Promoter | Preferential issue pursuant to share swap |
| Vupparapalli Pavani | 2.50 lakh | Non-Promoter | Conversion of Warrants into equity |
| Total | 17.50 lakh |
Shareholding Pattern Changes
The allotment significantly altered the shareholding structure of both investors:
Before Acquisition
| Investor | Equity Shares | Warrants | Total Holdings |
|---|---|---|---|
| Vupparapalli Chandra Sekhar Reddy | 1.50 lakh | 2.50 lakh | 4.00 lakh |
| Vupparapalli Pavani | 1.50 lakh | 2.50 lakh | 4.00 lakh |
| Combined | 3.00 lakh | 5.00 lakh | 8.00 lakh |
After Acquisition
| Investor | Equity Shares | Warrants | Total Holdings | Shareholding % |
|---|---|---|---|---|
| Vupparapalli Chandra Sekhar Reddy | 4.00 lakh | 0 | 4.00 lakh | 0.95% |
| Vupparapalli Pavani | 16.50 lakh | 0 | 16.50 lakh | 3.91% |
| Combined | 20.50 lakh | 0 | 20.50 lakh | 4.86% |
Capital Structure Impact
The preferential allotment resulted in substantial changes to the company's equity capital:
| Parameter | Before Allotment | After Allotment |
|---|---|---|
| Equity Share Capital | ₹10.77 crores | ₹42.22 crores |
| Number of Shares | 1.08 crore | 4.22 crore |
| Diluted Share Capital | ₹43.99 crores | |
| Diluted Number of Shares | 4.40 crore |
Regulatory Compliance
The transaction was conducted in full compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Vupparapalli Chandra Sekhar Reddy filed the required disclosure under Regulation 29(2) on behalf of both investors on January 15, 2026. The disclosure was submitted to BSE Limited, where the company's shares are listed under scrip code 512600.
Transaction Structure
The allotment involved two primary mechanisms - conversion of existing warrants into equity shares and preferential issue through share swap arrangements. The warrant conversions totaled 5.00 lakh shares (2.50 lakh each for both investors), while the share swap arrangement contributed 12.50 lakh additional shares to Vupparapalli Pavani's holdings. This strategic allocation demonstrates the company's approach to strengthening its equity base through targeted investor participation.
Historical Stock Returns for Astal Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.91% | -3.54% | -11.75% | -0.03% | -30.98% | +543.54% |
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
